Tumour immunology and immunotherapy
Group 1 of the Inserm (National Institute of Health and Medical Research) UMR 1015 research unit, « Tumour immunology and immunotherapy of cancer », is under the direction of Professor Laurence Zitvogel. Between 2015 and 2018 it will be exploring three lines of research:
- Gut microbiota and pro- or anti-tumour inflammatory/immunological activity, by measuring the effect of specific therapies on their regulation,
- Individualised immunotherapy with monoclonal antibodies tailored according to the tumour microenvironment (varying as a function of the histology and the patient). The mode of action of these immunomodulators will be studied and tests to predict the response to these antibodies or combinations of them will be developed,
- Characterisation of NK (natural killer) cells invading tumours: their role, specific receptors and differentiation.
The CICBT507 (CICBT = Centre for Clinical Investigation in Biotherapies of Cancer) unit under the triple aegis of the Gustave Roussy Institute, the Curie Institute and INSERM plans to develop novel therapeutic approaches in immuno-oncology, using new animal models and immunomonitoring tools. This group will be working closely with the Cellular Therapy Unit (in particular using dendritic cell-derived exosomes) and will be involved in Phase I-II-III clinical trials planned in our centres.